Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:2531 |
Name | hematologic cancer |
Definition | An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes. |
Source | DiseaseOntology.org |
Alt Ids | DOID:2532 DOID:1034 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00074490 | Phase II | Cyclophosphamide Cyclosporine Rituximab Doxorubicin Etoposide Filgrastim Vincristine Sulfate Fludarabine | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | Terminated | USA | 0 |
NCT00167180 | Phase II | Cyclophosphamide + Fludarabine | Post Transplant Donor Lymphocyte Infusion | Terminated | USA | 0 |
NCT00305682 | Phase II | Sirolimus Mycophenolate mofetil anti-thymocyte globulin Cyclophosphamide Fludarabine | Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant | Completed | USA | 0 |
NCT00520130 | Phase Ib/II | Cytarabine + Fludarabine Alemtuzumab + Cyclosporine Cyclophosphamide + Doxorubicin + Etoposide + Fludarabine + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Fludarabine + Prednisone + Vincristine Sulfate Methotrexate + Sirolimus + Tacrolimus Filgrastim | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | Completed | USA | 0 |
NCT00697632 | Phase I | Glesatinib | Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies | Completed | USA | CAN | 1 |
NCT01203722 | Phase Ib/II | Tacrolimus Sirolimus Cyclophosphamide + Fludarabine + Mycophenolate mofetil | Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | Recruiting | USA | 0 |
NCT01231412 | Phase III | Sirolimus Fludarabine Cyclosporine + Mycophenolate mofetil | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | Completed | USA | DNK | DEU | 0 |
NCT01339871 | Phase I | Vorinostat Pazopanib | Phase I Study of Pazopanib and Vorinostat | Completed | USA | 0 |
NCT01375842 | Phase I | Atezolizumab | A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | GBR | FRA | ESP | 0 |
NCT01376310 | Phase II | Docetaxel + Trametinib Erlotinib + Trametinib Trametinib Pemetrexed Disodium + Trametinib Carboplatin + Trametinib Nab-paclitaxel + Trametinib Gemcitabine + Trametinib Everolimus + Trametinib | GSK1120212 Rollover Study | Terminated | USA | NLD | FRA | CAN | 2 |
NCT01529827 | Phase II | Melphalan Methotrexate Tacrolimus Mycophenolate mofetil Fludarabine | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT01531894 | Phase II | Afuresertib | Continuation Study of the Oral AKT Inhibitor GSK2110183 | Completed | USA | IRL | CAN | AUS | 1 |
NCT01619761 | Phase I | Rituximab Fludarabine + Lenalidomide + Melphalan Mycophenolate mofetil Tacrolimus | Natural Killer (NK) Cells in Cord Blood Transplantation | Unknown status | USA | 0 |
NCT01635712 | Phase I | SNX-5422 | Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies | Completed | USA | 0 |
NCT01643603 | Phase Ib/II | Dasatinib | Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | Terminated | USA | 0 |
NCT01664910 | Phase Ib/II | Bendamustine + Fludarabine + Inotuzumab ozogamicin Rituximab anti-thymocyte globulin Tacrolimus | CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies | Completed | USA | 0 |
NCT01760655 | Phase II | Tacrolimus Cyclophosphamide + Fludarabine + Thiotepa Mycophenolate mofetil | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | Completed | USA | 0 |
NCT01767766 | Phase I | Umbralisib | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT01831726 | Phase II | Dovitinib | Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | Completed | USA | 0 |
NCT01833169 | Phase II | Buparlisib | BKM120 for Patients With PI3K-activated Tumors | Completed | USA | 0 |
NCT01885195 | Phase II | Binimetinib | MEK162 for Patients With RAS/RAF/MEK Activated Tumors | Completed | USA | 0 |
NCT01919619 | Phase II | Ipilimumab + Lenalidomide | Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | Completed | USA | 0 |
NCT01954316 | Phase I | CFI-400945 | A Study of CFI-400945 Fumarate in Patients With Advanced Cancer | Completed | USA | CAN | 0 |
NCT01981187 | Phase II | Encorafenib | LGX818 for Patients With BRAFV600 Mutated Tumors | Terminated | USA | 0 |
NCT02002689 | Phase II | Sonidegib | LDE225 for Patients With PTCH1 or SMO Mutated Tumors | Terminated | USA | 0 |
NCT02065869 | Phase Ib/II | Rivogenlecleucel Rimiducid | Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant | Terminated | ITA | GBR | 0 |
NCT02074839 | Phase I | Ivosidenib | Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Recruiting | USA | FRA | 0 |
NCT02076997 | Phase I | Methotrexate | Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate | Completed | USA | 0 |
NCT02118311 | Phase II | Fludarabine Cyclophosphamide | T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After a Non-Myeloablative Umbilical Cord Blood Transplantation | Withdrawn | USA | 0 |
NCT02160041 | Phase II | Infigratinib | BGJ398 for Patients With Tumors With FGFR Genetic Alterations | Terminated | USA | 0 |
NCT02162888 | Phase I | Bendamustine | A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients | Completed | USA | 0 |
NCT02186821 | Phase II | Ceritinib | Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) | Terminated | USA | 0 |
NCT02187783 | Phase II | Ribociclib | LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) | Completed | USA | 0 |
NCT02223598 | Phase I | CB-5083 CB-5083 + Dexamethasone | A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102) | Terminated | USA | CAN | 0 |
NCT02272998 | Phase II | Ponatinib | Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. | Active, not recruiting | USA | 0 |
NCT02333162 | Phase I | Mycophenolate mofetil Tacrolimus Fludarabine + Melphalan | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | Recruiting | USA | 0 |
NCT02342613 | Phase I | Activated PTCgamma MILs | Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation | Completed | USA | 0 |
NCT02343679 | Phase II | Ceritinib | Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies | Withdrawn | USA | 0 |
NCT02352558 | Phase I | Imatinib Napabucasin Bortezomib Ibrutinib Dexamethasone | A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT02362035 | Phase Ib/II | Acalabrutinib Pembrolizumab | ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145) | Active, not recruiting | USA | 0 |
NCT02369029 | Phase I | BAY 1238097 | BAY1238097, First in Man | Terminated | USA | GBR | FRA | FIN | DEU | CHE | 0 |
NCT02381886 | Phase I | IDH305 | A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | Active, not recruiting | USA | NLD | ESP | DEU | CAN | BEL | AUS | 1 |
NCT02418000 | Phase Ib/II | E6201 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation | Terminated | USA | 0 |
NCT02419755 | Phase II | Cytarabine Mercaptopurine Methotrexate Pegaspargase Vorinostat Doxorubicin Bortezomib Dexamethasone Mitoxantrone Prednisone | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | Terminated | USA | 0 |
NCT02423915 | Phase Ib/II | Filgrastim Rituximab Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus | Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | Completed | USA | 0 |
NCT02452697 | Phase II | DUK-CPG-001 | Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT | Active, not recruiting | USA | 0 |
NCT02484053 | Phase I | Rituximab | Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders | Completed | USA | 0 |
NCT02492737 | Phase I | Vorasidenib | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | Completed | USA | FRA | 0 |
NCT02494258 | Phase II | Azacitidine | A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders. | Active, not recruiting | USA | GBR | 0 |
NCT02508038 | Phase I | Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa | Recruiting | USA | 0 |
NCT02561988 | Phase I | Avapritinib | (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies | Completed | USA | GBR | 0 |
NCT02571036 | Phase I | Ripretinib | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | Completed | USA | NLD | ITA | GBR | DEU | CAN | 0 |
NCT02576496 | Phase I | Tinostamustine | Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | Completed | USA | NLD | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02584933 | FDA approved | Ceritinib | Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study | Active, not recruiting | USA | POL | LBN | ITA | FRA | ESP | DEU | CZE | BRA | BGR | BEL | AUS | 9 |
NCT02588105 | Phase I | Olaparib AZD0156 | Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer | Completed | USA | GBR | ESP | 1 |
NCT02611063 | Phase I | Fostamatinib | Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant | Completed | USA | 0 |
NCT02612285 | Phase II | SNX-5422 | Study of SNX-5422 in TP53 Null Cancers | Terminated | USA | 0 |
NCT02639559 | Phase II | BKT140 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | Completed | USA | 0 |
NCT02658890 | Phase Ib/II | Ipilimumab + Linrodostat + Nivolumab Linrodostat + Nivolumab | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | Completed | USA | SWE | POL | NOR | ITA | FRA | FIN | ESP | DEU | CAN | AUS | 0 |
NCT02663518 | Phase I | TTI-621 | A Trial of TTI-621 for Patients With Hematologic Malignancies | Terminated | USA | CAN | 0 |
NCT02679131 | Phase I | Belinostat | To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment. | Terminated | USA | 0 |
NCT02680795 | Phase I | Belinostat | To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes | Completed | USA | 0 |
NCT02711137 | Phase Ib/II | INCB057643 | A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | Terminated | USA | FRA | BEL | 0 |
NCT02774291 | Phase I | Aldesleukin Cyclophosphamide + Fludarabine Filgrastim | Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1 | Terminated | USA | 0 |
NCT02813135 | Phase Ib/II | Ribociclib + Temozolomide + Topotecan Adavosertib + Carboplatin Enasidenib Lirilumab + Nivolumab Irinotecan + Olaparib | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART) | Recruiting | NLD | ITA | GBR | FRA | ESP | DNK | DEU | 0 |
NCT02862275 | Phase 0 | Atezolizumab | Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | Active, not recruiting | USA | CAN | 0 |
NCT02889445 | Expanded access | DM-CHOC-PEN | A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers | No longer available | USA | 0 |
NCT02921919 | Phase II | Talazoparib | Open-Label Extension and Safety Study of Talazoparib | Completed | USA | POL | HUN | GBR | FRA | DEU | CAN | 2 |
NCT02937675 | Phase Ib/II | Tomivosertib | A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies | Terminated | USA | 0 |
NCT02985554 | Phase I | Nivolumab | Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT03075696 | Phase I | Glofitamab-gxbm + Obinutuzumab + Tocilizumab | A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Recruiting | USA | POL | NZL | ITA | FRA | FIN | ESP | DNK | CZE | CAN | BEL | AUS | 1 |
NCT03151057 | Phase I | Idelalisib | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | Terminated | USA | 0 |
NCT03219268 | Phase I | MGD013 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | Completed | USA | POL | ESP | BGR | AUS | 3 |
NCT03236857 | Phase I | Venetoclax | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | Completed | USA | NLD | GBR | FRA | DEU | CHE | CAN | AUS | 0 |
NCT03263637 | Phase I | AZD4573 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Completed | NLD | GBR | DEU | 0 |
NCT03386513 | Phase Ib/II | IMGN632 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03386526 | Phase Ib/II | APG-1387 | APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies | Completed | USA | 0 |
NCT03420430 | Expanded access | GL-ONC1 | Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care | No longer available | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
NCT03440437 | Phase I | FS118 | FS118 First in Human Study in Patients With Advanced Malignancies After PD-1/PD-L1 Containing Therapy | Terminated | USA | FRA | 0 |
NCT03485547 | Phase I | Venetoclax | Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Active, not recruiting | USA | 0 |
NCT03512340 | Phase I | SRF231 | Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | Completed | USA | CAN | 0 |
NCT03533283 | Phase I | Glofitamab-gxbm + Obinutuzumab Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq + Tocilizumab Atezolizumab + Glofitamab-gxbm + Obinutuzumab + Tocilizumab | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Active, not recruiting | USA | ITA | ISR | GBR | ESP | DNK | BEL | 0 |
NCT03555955 | Phase I | CPX-351 | A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 | Completed | USA | CAN | 0 |
NCT03588936 | Phase I | Nivolumab + Tocilizumab | Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant | Terminated | USA | 0 |
NCT03711604 | Phase Ib/II | Tenalisib | Compassionate Use Study of Tenalisib (RP6530) | Completed | USA | POL | 1 |
NCT03733249 | Phase Ib/II | Rimiducid + Rivogenlecleucel | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | Terminated | ITA | 0 |
NCT03739606 | Phase II | Flotetuzumab | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Withdrawn | 0 | |
NCT03837899 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab for Pediatric Malignancies | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03838926 | Phase I | Trichostatin A | Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies | Unknown status | USA | 0 |
NCT03849651 | Phase II | TCR alpha/beta+/CD19+ depleted hematopoietic cells CD45RA-depleted donor lymphocytes anti-thymocyte globulin + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Mesna + Thiotepa Blinatumomab | TCRalphabeta-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03850366 | Phase II | Bortezomib + Cyclophosphamide | HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib | Recruiting | USA | 0 |
NCT04020185 | Phase Ib/II | IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Completed | USA | 0 |
NCT04077723 | Phase I | Obinutuzumab + RO7227166 + Tocilizumab Glofitamab-gxbm + Obinutuzumab + RO7227166 + Tocilizumab | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | BEL | AUS | 0 |
NCT04130542 | Phase I | LVGN6051 | Phase 1 Trial of LVGN6051 as Single Agent and in Combination Therapy in Advanced or Metastatic Malignancy | Active, not recruiting | USA | 0 |
NCT04184869 | Phase I | Belinostat Atazanavir + Belinostat | Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials | Completed | USA | 0 |
NCT04185831 | Phase II | Atezolizumab Niraparib Cobimetinib Everolimus | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial (MEGALiT) | Active, not recruiting | SWE | 0 |
NCT04216524 | Phase II | Cyclophosphamide + Dexamethasone + Methotrexate + Rituximab + Venetoclax + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Methotrexate + Rituximab + Venetoclax + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Venetoclax + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Venetoclax + Vincristine Sulfate Cytarabine + Methotrexate + Methylprednisolone + Rituximab + Venetoclax Tagraxofusp-erzs + Venetoclax Cytarabine + Methotrexate + Rituximab + Venetoclax Tagraxofusp-erzs Mercaptopurine + Methotrexate + Prednisone + Tagraxofusp-erzs + Venetoclax + Vincristine Sulfate | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | Recruiting | USA | 0 |
NCT04241835 | Phase I | Tazemetostat | A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies | Recruiting | USA | SVK | POL | FRA | BEL | 0 |
NCT04347226 | Phase II | BMS-986253 | Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19 | Terminated | USA | 0 |
NCT04537715 | Phase I | Itraconazole + Tazemetostat Rifampin + Tazemetostat | Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | Completed | USA | ESP | 0 |
NCT04603001 | Phase I | LY3410738 | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | Active, not recruiting | USA | ISR | FRA | FIN | ESP | DEU | CAN | BEL | AUS | 3 |
NCT04605614 | Phase I | Pembrolizumab | 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression | Withdrawn | 0 | |
NCT04681105 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | Active, not recruiting | USA | 0 |
NCT04684108 | Phase I | SG301 | SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies | Active, not recruiting | 1 | |
NCT04764474 | Phase I | HMPL-306 | A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH | Recruiting | USA | ESP | 0 |
NCT04772989 | Phase I | AB308 + Zimberelimab | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12) | Active, not recruiting | USA | POL | ESP | 0 |
NCT04817956 | Phase II | Ceritinib Melphalan Cobimetinib + Vemurafenib Alectinib Pemigatinib Entrectinib Bortezomib Dostarlimab-gxly Atezolizumab Alpelisib Atezolizumab + Bevacizumab Olaparib Selpercatinib Capmatinib Dactinomycin Dabrafenib + Trametinib Vismodegib Niraparib Imatinib Pertuzumab/trastuzumab/hyaluronidase-zzxf | Improving Public Cancer Care by Implementing Precision Medicine in Norway (IMPRESS-N) | Recruiting | NOR | 0 |
NCT05041309 | Phase II | KITE-585 KITE-222 Brexucabtagene autoleucel KITE-718 axicabtagene ciloleucel KITE-439 | Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells | Enrolling by invitation | USA | NLD | ISR | GBR | FRA | DEU | CAN | AUS | 1 |
NCT05092451 | Phase Ib/II | CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | Recruiting | USA | 0 |
NCT05110742 | Phase Ib/II | CAR.5/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances | Recruiting | USA | 0 |
NCT05159245 | Phase II | Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE) | Recruiting | FIN | 0 |
NCT05219513 | Phase I | Glofitamab-gxbm + Obinutuzumab + RO7443904 + Tocilizumab Glofitamab-gxbm + Obinutuzumab + RO7443904 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Terminated | USA | ITA | GBR | FRA | DNK | AUS | 0 |
NCT05284032 | Phase I | Isatuximab | A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001) | Terminated | USA | 0 |
NCT05303532 | Phase III | Durvalumab | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab (ROSY-D) | Enrolling by invitation | USA | TUR | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUS | ARG | 13 |
NCT05476770 | Phase I | Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT05609942 | Phase Ib/II | Elenestinib Azacitidine + Elenestinib | Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE) | Recruiting | USA | NOR | NLD | FRA | ESP | DEU | BEL | 0 |
NCT05665062 | Phase I | Cyclophosphamide + Fludarabine STK-009 + SYNCAR-001 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | Recruiting | USA | 0 |
NCT05694364 | Phase I | PRGN-3007 Cyclophosphamide Cyclophosphamide + Fludarabine | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05768178 | Phase II | Cobimetinib + Vemurafenib | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (DETERMINE) | Recruiting | GBR | 0 |
NCT05828459 | Phase I | Lenalidomide + OT-A201 OT-A201 OT-A201 + Paclitaxel Bevacizumab + OT-A201 OT-A201 + Pomalidomide | First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | Recruiting | FRA | 0 |
NCT06325748 | Phase I | SENTI-202 | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | Recruiting | USA | AUS | 0 |
NCT06345027 | Phase I | CD70-CAR-T cells | CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) (CASEY) | Not yet recruiting | USA | 0 |